Cancer Treatment Results from Tubercin reported by ArTec, Inc.RENO, Nev. -- ArTec, Inc., (Pink Sheets:ATKJ) announced that Dr. Tai Ho Chung, formulator of Tubercin and the Company's scientific advisor, along with members of a research team from Kyungpook National University History of Kyungpook National University Kyungpook National University (KNU) was founded in the spirit of truth, pride, and service: pursuing truth through academic study; developing pride as a member of the University and future leader; and inspiring service towards the Hospital, Daegu, South Korea, recently reported the successful results on the long term treatment of a 26 year old breast cancer patient. Although already in an advanced stage of the disease, the subject after a treatment protocol that combined Tubercin with conventional radiation has been in remission Extinguishment or release of a debt. A remission is conventional when it comes about through an express grant to the debtor by a creditor. It is tacit when the creditor makes a voluntary surrender of the original title to the debtor under private signature constituting the for the past three years through November 2004. Treatment with Tubercin commenced in the year 2000, primarily because the patient had not responded well to conventional therapies. Three years after the initial treatment, remarkably, the patient remains in remission. Dr. Chung noted that, "This particular case demonstrates clinically that Tubercin is effective, as an adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. to radiation, and can be successfully combined with conventional cancer treatments without the fear of adverse side-effects." He further commented, "There are other cases where Tubercin has been successful with breast cancer as well as other cancers when administered as the only treatment." Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion